Jayson Dallas
MD, MBA

Jayson was most recently Chief Executive Officer & President of Rivus Pharmaceuticals, a private biotechnology company developing the first controlled metabolic accelerators for the treatment of obesity and the resulting cardio-metabolic complications. He assumed that role in 2023, having been Executive Chairman of the company since 2021. Previously, as Chief Executive Officer & President of Aimmune Therapeutics (Nasdaq:AIMT), he led the approval and launch of the the first ever approved therapy for peanut allergy. Aimmune was acquired by Nestlé Health Science for $2.6B in October 2020, in the midst of the pandemic.

From 2015-2018, Jayson was the first Chief Commercial Officer of Ultragenyx Pharmaceuticals, where he built the Global commercial organization from the ground up.

Before making the transition into biotech, Jayson was the General Manager of Roche in the United Kingdom after having been the Global Product Strategy Head for Immunology and Ophthalmology at Roche / Genentech.

Prior to that, Jayson spent 6 years at Novartis where he held several positions in the US Commercial organization, leading up to serving as the Head of the Specialty Medicines Operating Unit.

Before Novartis, Jayson held a variety of commercial and medical affairs roles at Pharmacia / Pfizer, Roche in Switzerland and Procter & Gamble Pharmaceuticals.

Jayson presently serves on the Boards of Galecto Inc (NASDAQ:GLTO) and Faeth Therapeutics (Private). He was previously a member of the Board of directors of Arena Pharmaceuticals (NASDAQ:ARNA), which was sold to Pfizer in 2021 for $6.7B, and Antag Pharmaceuticals (Private).

Jayson earned his MD from the University of the Witwatersrand in Johannesburg, South Africa and his MBA from the Hult Ashridge Business School in Berkhamstead, United Kingdom.